Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World antibiotic study cut short: what we can learn

NCT ID NCT05487586

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tracked how the antibiotic ceftazidime-avibactam is used in real hospital settings in China for serious infections like pneumonia and abdominal infections. Researchers planned to enroll 450 patients but the study was terminated early. The goal was to see how often the drug clears the infection and how bacteria respond, providing insights for doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ceftazidime-avibactam
What this could lead to
If successful, this study could provide real-world data on how well ceftazidime-avibactam works against tough hospital infections in everyday practice.
What could go wrong
This was an observational study that was terminated early, so results may be limited. It does not test a new treatment, only observes current use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

220 people

The number who actually took part.

Started

Oct 2022

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hospitalized patients treated with CAZ AVI for ≥1 dose in approximately 20 study sites.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria： * Initiate ≥1 dose of ceftazidime-avibactam during hospitalization. * Aged ≥ 18 years old at the time of the informed consent signature. * Provide signed informed consent. Exclusion criteria： * Are enrolled in any clinical trial, including enrollment in non interventional studies. * Pregnant women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Complicated intra abdominal infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Healthcare-Associated Pneumonia infectious peritonitis nosocomial infection Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Complicated intra abdominal infections Hospital-acquired pneumonia Ventilator acquired pneumonia

Contacts and locations

Locations

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Henan Provincial People's Hospital

    Zhengzhou, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • Shanghai Tenth People's Hospital

    Shanghai, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • The Affiliated People's Hospital of Ningbo University

    Ningbo, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China

  • The First affiliated Hospital of Anhui Medical University

    Hefei, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • The Second People's Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, China

  • Tianjin Medical University General Hospital

    Tianjing, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Zhongda Hospital Southeast University

    Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.